Article
作者: Rahman, Mohammed Masudur ; Hatemi, İbrahim ; Kaya, Berrin Yalınbas ; Barbaro, Maria Raffaella ; Lobo, Beatriz ; Melcarne, Luigi ; Falangone, Francesca ; Hod, Keren ; Tornkvist, Navkiran ; Zoli, Marco ; Bellini, Massimo ; Maggio, Marcello ; Bengi, Goksel ; Salvi, Daniele ; Yapali, Suna ; Celebi, Altay ; Bugdayci, Mehmet Sait ; Venturi, Alessandro ; Fusaroli, Pietro ; Di Sabatino, Antonio ; Urun, Yonca Yilmaz ; Maconi, Giovanni ; Barbara, Giovanni ; Santos, Javier ; Bor, Serhat ; Kolokolnikova, Olga ; Alıs, Esra Ergun ; Koc, Elif Sitre ; Lukic, Snezana ; Portincasa, Piero ; Serra, Jordi ; Viale, Pierluigi ; Ebik, Berat ; Tureyen, Ali ; Gionchetti, Paolo ; Mohamed, Salem Youssef ; Ghoshal, Uday C ; Philippou, Elena ; Sirin, Goktug ; Miftode, Egidia ; Pullukcu, Husnu ; Calıskan, Ali Riza ; Kagramanova, Anna ; Akyol, Deniz ; Dumitrascu, Dan ; Trajkovska, Meri ; Ricci, Chiara ; Pietrangelo, Antonello ; Marasco, Giovanni ; Sjölund, Jessica ; Borghi, Claudio ; Sapmaz, Ferdane Pirincci ; Colecchia, Antonio ; Stanghellini, Vincenzo ; Danese, Silvio ; Cacciari, Giulia ; Binicier, Hatice Cilem ; Simren, Magnus ; Cremon, Cesare ; Bordin, Dmitry ; Yağcı, Munkhtsetseg Banzragch ; Lee, Yeong Yeh ; De Giorgio, Roberto ; Drug, Vasile ; Kacmaz, Huseyin ; Corradini, Elena ; Eskazan, Tugce
ObjectivesThe long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut–brain interaction after hospitalisation for SARS-CoV-2 infection.DesignGI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires.ResultsThe study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls.ConclusionCompared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls.Trial registration numberNCT04691895.